key: cord-0768465-mhyishpi
authors: Jampani, Mahesh; Chandy, Sujith J.
title: Increased antimicrobial use during COVID‐19: The risk of advancing the threat of antimicrobial resistance
date: 2021-12-14
journal: Health Sci Rep
DOI: 10.1002/hsr2.459
sha: f6b52e7672f946dd1f6937eafa764a539d71f569
doc_id: 768465
cord_uid: mhyishpi

nan

The repeated waves of the novel coronavirus disease across the world have resulted in major issues in different facets of life, especially in healthcare. In low-and middle-income countries (LMICs) such as India, the effects of the pandemic have been devastating, driving communities, hospitals, and government into a crisis mode. 1 There were a series of lockdowns and other pandemic-related restrictions since March 2020, which appeared to have curbed the infection rates in the first wave. However, since April 2021, the number of people infected and deaths associated with the second wave of COVID-19, specifically due to the delta variant, has been alarming. As a consequence, governments and scientific communities have been keen on finding an effective treatment for COVID-19.

Many drugs were proposed to minimize morbidity and mortality, even though evidence regarding effectiveness was inconclusive. However, the fear among the public often heightened through the media, and the need for some form of treatment encouraged the rampant use of vitamins, immunity boosters, combination drugs or cocktail of antivirals, antibiotics, steroids, and antifungals. [2] [3] [4] The popular antimicrobials frequently used include hydroxychloroquine, ivermectin, favipiravir, doxycycline, azithromycin, etc. 5 Purchasing these antimicrobials require a prescription; however, community intake of these drugs surged with over-the-counter purchases, probably due to the desperate situation and the need to take some form of treatment.

As a result, several antimicrobial drug sales skyrocketed, and many of them became out of stock in May 2021. 6 Increased antimicrobial sales and consequent consumption during COVID-19 might be due to various reasons and factors. These include: symptoms of COVID-19, especially cough and fever, could be mistaken for a bacterial infection and vice versa; some studies have tried out several antimicrobials for COVID-19 such as hydroxychloroquine, ivermectin, and azithromycin, and doctors, therefore, tend to prescribe 7 ; many research studies though lacking conclusive evidence later become pieces of information which floated around in the news and social media, leading to purchase of these medicines by the public; as there is still no cure as per evidence, people are desperate and therefore take whatever they can, including antimicrobials.

Such increased sales and intake of antimicrobials may directly contribute to increased antimicrobial resistance (AMR).

AMR has been recognized as a global public health emergency and has been on the agenda of the United Nations General Assembly (UNGA). 8 (Figure 1 ). This possible consumption may have become a behavioral practice to minimize the risks associated with COVID-19 and save lives. This raises an important question: whether the treatment practices associated with the current pandemic crisis will further worsen the "silent pandemic" of AMR, its evolution in society and the environment. 10 Even though the current COVID-19 mortality rates appear very high, the faceless nature of AMR, its ever-evolving nature, its multidimensional effects, and the complexity of arriving at solutions suggests that AMR would be a much bigger threat in terms of infection and death rates. 11 It is well known that antibiotic use is a major contributing factor toward rising AMR. 12 Consequently, antibiotic overuse and misuse during this pandemic and future ones need to be recognized and counter-strategies devised to prevent a further rise in AMR. 4 Recent research studies have shown that several antibiotics, especially doxycycline and azithromycin, are ineffective against treating COVID-19. 13 To add another dimension, a recent study by Chakraborty and colleagues in Chennai in September 2020 detected high concentrations of azithromycin in wastewater, possibly reflecting its increased community consumption. 14 Furthermore, during the COVID-19 pandemic, overall antimicrobial consumption from the community and hospitals might be significantly higher. 4, 14 Therefore, the total amount of antimicrobial loadings entering through hospital wastewater, human feces, and urine into the natural environment needs attention. The main concern is whether these potentially very large amounts of antimicrobial loadings within the last year will increase selection pressure in the natural environment and influence environmental bacteria to become resistant.

At the governance level, policymakers should be aware of these extremely large antimicrobial consumption patterns during the pandemic and take actions including awareness building for the public, guidelines for healthcare professionals, and overall stricter regulatory implementation to optimize antibiotic use and thereby mitigate future risk of infections associated with AMR. Over the years, antimicrobial resistance stewardship programs have helped to optimize prescribing antimicrobials, but these efforts need to be doubled during the pandemic and beyond. The brief analysis done with Google search trends suggests that coherent approaches are needed to understand and tackle the possibility of COVID-19-associated antimicrobial consumption and its impact on infectious disease patterns so as to prevent a future catastrophe through the faceless pandemic of AMR. The corresponding author had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

The corresponding author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

The authors confirm that the data supporting the findings of this study are available within the article.

https://orcid.org/0000-0002-8925-719X

India's COVID-19 crisis: a call for international action

Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors -a survey

Clinical course and outcome of patients with COVID-19 in Mumbai City: an observational study

Empiric antibacterial therapy and community-onset bacterial Coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study

Safety and efficacy of ivermectin and doxycycline monotherapy and in combination in the treatment of COVID-19: a scoping review

Covid-19 medicine: key drugs, steroids in short supply

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial

High-level interactive dialogue on antimicrobial resistance. General Assembly of the United Nations

Tripartite plus -Recent update and memorandum of understanding on antimicrobial resistance

Resetting the agenda for antibiotic resistance through a health systems perspective

Tackling drug-resistant infections globally: final report and recommendations

Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem

Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial -PRINCIPLE Trial

First surveillance of SARS-CoV-2 and organic tracers in community wastewater during post lockdown in Chennai, South India: methods, occurrence and concurrence